Arbaclofen Placarbil

Summary

Arbaclofen Placarbil (CHEMBL2107312) is a phase-3 clinical-stage small molecule; indicated across 5 conditions including multiple sclerosis and gastroesophageal reflux disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 5 conditions
• Clinical trials: 2
• Chemistry: 399.9 Da · C19H26ClNO6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107312
Name	Arbaclofen Placarbil
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	11281011
Molecular formula	C19H26ClNO6
Molecular weight	399.9
InChIKey	JXTAALBWJQJLGN-KSSFIOAISA-N

SMILES: CC(C)[C@@H](OC(=O)C(C)C)OC(=O)NC[C@H](CC(=O)O)C1=CC=C(C=C1)Cl

IUPAC name: (3R)-3-(4-chlorophenyl)-4-[[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino]butanoic acid

Also known as: Arbaclofen placarbil, Arbaclofene placarbil, Arbaclofeno placarbilo, XP-19986, XP19986, ARBACLOFEN PLACARBIL

Patent coverage: 39 distinct patent families (120 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
multiple sclerosis	3	MONDO:0005301	MONDO:0005301
gastroesophageal reflux disease	2	MONDO:0007186	EFO:0003948
alcohol abuse	2	MONDO:0002046	MONDO:0007079

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00817986	PHASE2	COMPLETED	A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms
NCT02511886	PHASE2	COMPLETED	A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).